Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis.
Bioneedles are small hollow sugar based needles administered with a simple compressed air device. In the present study we investigate how incorporation of a subunit vaccine based on TB vaccine hybrid Ag85B-ESAT-6 adjuvated with CAF01 into Bioneedles affects its immunogenicity as well as its ability...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-11-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21124731/?tool=EBI |
| _version_ | 1818834440745385984 |
|---|---|
| author | Dennis Christensen Thomas Lindenstrøm Gijsbert van de Wijdeven Peter Andersen Else Marie Agger |
| author_facet | Dennis Christensen Thomas Lindenstrøm Gijsbert van de Wijdeven Peter Andersen Else Marie Agger |
| author_sort | Dennis Christensen |
| collection | DOAJ |
| description | Bioneedles are small hollow sugar based needles administered with a simple compressed air device. In the present study we investigate how incorporation of a subunit vaccine based on TB vaccine hybrid Ag85B-ESAT-6 adjuvated with CAF01 into Bioneedles affects its immunogenicity as well as its ability to protect against TB in a mouse model. The CMI response measured by IFN-γ and antigen specific CD4+ T-cells was, two weeks after the last vaccination, significantly lower in the group immunized with Bioneedle-incorporated vaccine compared to the conventional vaccine, using syringe and needle. However, at four, nine and 52 weeks after vaccination we observed similar high IFN-γ levels in the Bioneedle group and the group vaccinated using syringe and needle and comparable levels of antigen specific T-cells. Furthermore, the protective efficacy for the two vaccination methods was comparable and similar to BCG vaccination both six and 52 weeks after vaccination. These results therefore advocate the further development of the Bioneedle devises and applicators for the delivery of human vaccines. |
| first_indexed | 2024-12-19T02:34:51Z |
| format | Article |
| id | doaj.art-a26c904a27a04f4b940f7b735120be5d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-19T02:34:51Z |
| publishDate | 2010-11-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a26c904a27a04f4b940f7b735120be5d2022-12-21T20:39:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-11-01511e1504310.1371/journal.pone.0015043Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis.Dennis ChristensenThomas LindenstrømGijsbert van de WijdevenPeter AndersenElse Marie AggerBioneedles are small hollow sugar based needles administered with a simple compressed air device. In the present study we investigate how incorporation of a subunit vaccine based on TB vaccine hybrid Ag85B-ESAT-6 adjuvated with CAF01 into Bioneedles affects its immunogenicity as well as its ability to protect against TB in a mouse model. The CMI response measured by IFN-γ and antigen specific CD4+ T-cells was, two weeks after the last vaccination, significantly lower in the group immunized with Bioneedle-incorporated vaccine compared to the conventional vaccine, using syringe and needle. However, at four, nine and 52 weeks after vaccination we observed similar high IFN-γ levels in the Bioneedle group and the group vaccinated using syringe and needle and comparable levels of antigen specific T-cells. Furthermore, the protective efficacy for the two vaccination methods was comparable and similar to BCG vaccination both six and 52 weeks after vaccination. These results therefore advocate the further development of the Bioneedle devises and applicators for the delivery of human vaccines.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21124731/?tool=EBI |
| spellingShingle | Dennis Christensen Thomas Lindenstrøm Gijsbert van de Wijdeven Peter Andersen Else Marie Agger Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis. PLoS ONE |
| title | Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis. |
| title_full | Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis. |
| title_fullStr | Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis. |
| title_full_unstemmed | Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis. |
| title_short | Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis. |
| title_sort | syringe free vaccination with caf01 adjuvated ag85b esat 6 in bioneedles provides strong and prolonged protection against tuberculosis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21124731/?tool=EBI |
| work_keys_str_mv | AT dennischristensen syringefreevaccinationwithcaf01adjuvatedag85besat6inbioneedlesprovidesstrongandprolongedprotectionagainsttuberculosis AT thomaslindenstrøm syringefreevaccinationwithcaf01adjuvatedag85besat6inbioneedlesprovidesstrongandprolongedprotectionagainsttuberculosis AT gijsbertvandewijdeven syringefreevaccinationwithcaf01adjuvatedag85besat6inbioneedlesprovidesstrongandprolongedprotectionagainsttuberculosis AT peterandersen syringefreevaccinationwithcaf01adjuvatedag85besat6inbioneedlesprovidesstrongandprolongedprotectionagainsttuberculosis AT elsemarieagger syringefreevaccinationwithcaf01adjuvatedag85besat6inbioneedlesprovidesstrongandprolongedprotectionagainsttuberculosis |